711 HBM1022, a novel anti-CCR8 antibody depletes tumor-infiltrating regulatory T cells via enhanced ADCC activity, mediates potent anti-tumor activity with Keytruda

Benzer Materyaller

• Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis
  Yazar:: Lavinia Balan, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-05-01)
• Nivolumab (Opdivo) in PD-1 pathway inhibition: Enhancing immune response in recurrent oral squamous cell carcinoma
  Yazar:: J. Nandhini, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-09-01)
• Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
  Yazar:: Greg M Delgoffe, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-05-01)
• Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma
  Yazar:: Ayman Oweida, ve diğerleri
  Baskı/Yayın Bilgisi: (2017-10-01)
• Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®
  Yazar:: Jakob C. Stüber, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-09-01)